TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Life Sciences, Inc. (OTCPK:NNBP) ("Nanobac" or "the Company") has completed its first year as a public Company. The events and discoveries of the past year have reinforced our belief that we are at the forefront in the search for the causes and treatments of infectious diseases associated with pathological calcification. This sets forth the accomplishments of the last year, as well as our goals and expectations for the future.

The major accomplishments during the last 12 months include:
1. Completing the acquisition of Nanobac Oy, our Finland-based subsidiary that provided the foundation for the Company's intellectual property;

2. The issuance of patent coverage to expand and further protect the Company's intellectual property;

3. The discovery by independent researchers of a strong correlation between Nanobacteria infection and coronary artery calcification ("CAC") in asymptomatic individuals. This discovery was especially significant because it suggests that a simple blood test (provided by the Company and protected by its patents) might have predictive value for the future development of CAC. This could be similar to the PSA ("prostate specific antigen") test as a predictor of prostate cancer;

4. The discoveries by more than one independent researcher of Nanobacteria and/or Nanobacteria-like structures in calcified human arteries and cardiac valves. These discoveries provide continuing evidence of the Company's underlying premise that Nanobacteria is an infectious agent that ultimately causes pathological calcification;

5. The discovery by Mayo Clinic that Nanobacteria contain genetic material, an essential component for life. This discovery provides evidence relative to an ongoing scientific debate about whether or not Nanobacteria is a unique form of life. The existence of genetic material would confirm that it is a unique life form. However, the ultimate resolution of the debate is not necessarily relevant to the Company. Many infectious agents (such as viruses) have a parasitic existence in the human body and are thus not unique forms of life;

6. The discovery by independent researchers of nano-size organisms (with the presence of genetic material) and characterized as Nanobacteria, in kidney stones;

7. The discoveries by independent researchers of Nanobacteria in ovarian cancer cells; and,

8. The continued beneficial results of patients using the various therapies developed by the Company.

The major goals for the future include:

1. To evaluate and define the research and development objectives of the Company that will accommodate, as a high priority, the introduction of our products and technology to the marketplace;

2. To determine and obtain the capital needed to accomplish the Company's mission; and,

3. To find strategic partners to accelerate the commercialization of the Company's products and technologies.

Alexander Edwards and John Stanton have worked together to "set the table" for the Company's future. Alex's contributions to the Company have been invaluable in the achievements of the last year, as well as in defining our future goals. He has brought the appropriate people to the Company to complete our mission. Alex has decided to resign as the CEO of Nanobac. John Stanton will resume the CEO duties and looks forward to working with our team to accomplish our goals. Alex will continue to assist the Company in a consultative capacity.

Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobaclifesciences.com.